Status and phase
Conditions
Treatments
About
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
70 participants in 2 patient groups
Loading...
Central trial contact
Brandon Sookdeo
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal